AIM ImmunoTech completes dosing in pancreatic cancer trial

AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.

Original reporting
Published Nov 13, 2026, 1:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:50 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AIM
Bullish
medium confidence
Mentioned
$AIM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AIMBullishLow
01

Why it matters

The dosing milestone moves the company closer to a data readout that could materially affect valuation, but short‑term price movement is likely muted until efficacy results are released.

02

Market read

Primary biotech news with limited immediate market impact; relevance peaks around the upcoming efficacy readout.

03

What to watch

The company's cash runway is limited (~$7 M), which could constrain further development if additional funding is not secured.

Relevance 7/10Novelty 7/10Timing: immediate

Background

AIM ImmunoTech is a micro‑cap biotech focused on TLR‑3 agonist Ampligen, pursuing multiple oncology and infectious disease programs.

Company-level read

Ticker impact

$AIMBullishMedium confidence
Context

AIM ImmunoTech announced completion of dosing in its Phase 2 DURIPANC trial for metastatic pancreatic cancer.

Expected impact

potential slight upward pressure as investors price in upcoming efficacy data.

Evidence & confidence

No efficacy data yet, but trial advancement is a positive catalyst for a micro‑cap biotech.

Market effects

Adds to the pipeline momentum for pancreatic cancer immunotherapies, modestly supporting the biotech sector.

Limited to U.S. biotech investors; no broader regional effect.

Low global relevance beyond niche oncology investors.

Counterpoint

Without efficacy data, the trial completion may be over‑hyped; the stock could remain flat or decline if results disappoint.

Key entities

  • AstraZeneca

    Provides Imfinzi, the checkpoint inhibitor combined with Ampligen in the trial.

  • Revolution Medicines

    Potential collaborator on RAS‑targeted combination therapies.

Related articles